TEOXANE PRODUCT SAFETY AND SATISFACTION

PRODUCT SAFETY AND SATISFACTION

TEOSYAL ® PURESENSE REDENSITY 2

TEOSYAL ® PURESENSE REDENSITY 2  - light up your look

With over 9 years of expertise and more than 2 millions of injections worldwide1,2, Teoxane’s TEOSYAL ® PURESENSE REDENSITY 2 is the 1st & only one hyaluronic acid gel designed for the treatment of under eye hollows 2-4

TEOSYAL ® PURESENSE REDENSITY 2,  the Hyaluronic Acid  filler with a rheological profile specifically designed to treat infraorbital hollows

TEOSYAL ® PURESENSE REDENSITY 2,  the Hyaluronic Acid  filler with a rheological profile specifically designed to treat infraorbital hollows3:

 

LOW HYGROSCOPY

for immediate and natural correction 4

 

LOW PRESSURE ON TISSUES

For a decreased risk of oedema 4

 

GOOD SPREADABILITY

For a better postionning of the gel 4

 

GOOD TISSUE INTEGRATION  & ACTION ON SKIN THICKNESS

For hydration and improvement of the ageing skin 22

 

FILLER CHARACTERISTICS FOR THE UNDER EYE REGION

FILLER CHARACTERISTICS FOR THE UNDER EYE REGION - Dr Sabrina Shah-Desai

In a recent international survey, practitioners reported that the most important outcomes of TEOSYAL® PURESENSE REDENSITY 2  for their patients include:

 

- Natural-looking results 16

-Immediate results 16

-Youthful looks 16

-Up to 12 months duration 14

PROVEN SAFETY OVER YEARS

TEOSYAL® PURESENSE REDENSITY 2  GOOD SAFETY PROFILE

TEOSYAL® PURESENSE REDENSITY 2  GOOD SAFETY PROFILE

 

Annual average of 21:

 

Less than 2 ADVERSE REACTIONS per 10,000 sold syringes

Less than 2 cases of TYNDALL EFFECT per 100,000 sold syringes

Less than 1.5 cases of SKIN OEDEMA per 10,000 sold syringes

TEOSYAL ® PURESENSE REDENSITY 2 SAFETY RECOGNIZED IN A CLINICAL TRIAL2

 

TEOSYAL ® PURESENSE REDENSITY 2 SAFETY RECOGNIZED IN A CLINICAL TRIAL 2

Most side effects reported were mild, temporary and correctable2

 

 

During the clinical trial

• Mainly mild and transient post-injection reactions

• No blue discoloration / Tyndall effect (after 1 month)

• No need for hyaluronidase

• No unpleasant malar swelling

 

 

* Multicentric and international study: 2012/2013. 33 practitioners,151 patients (86% of women and 14% of men).
Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation.
Indications: 93% of patients were injected in the tear trough area.
Adverse event included Swelling (11,6%), Bruising(10,7%), Redness (6,3%), Blue discoloration (0,9%), Other (1,8%)

Reducing the risk of adverse event in the under eye region

One of the most common adverse events in the scientific literature is Tyndall effect which is a blue gray discoloration under the eye. […] if you're using REDENSITY 2 and you're injecting supraperiosteally, you shouldn't be having this risk

Dr. Sabrina Shah-Desai

Oculoplastic surgeon - United Kingdom

An easy injection for a reliable practice2

An easy injection for a reliable practice - TEOSYAL ® PURESENSE REDENSITY 2

TEOSYAL RHA® 4

SOFT & DYNAMIC VOLUMIZING IN THE MID CHEEK

TEOSYAL RHA® 4  SOFT & DYNAMIC VOLUMIZING IN THE MID CHEEK

As midface volume deficit increases, tear trough severity increases significantly. Adding volume to the midface using hyaluronic acid dermal filler can help reduce the appearance of tear troughs.

Therefore, midface volume deficit is adequately treated first prior to the infraorbital hollow.12

TEOSYAL RHA® 4,  the volumizer designed to provide soft volume enhancement and facial dynamism to facilitate natural-looking facial expressions 5,6,19,20

 

#Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL

 

TEOSYAL RHA® 4 rheological profile

TEOSYAL RHA® 4 rheological profile6

 

LOW BDDE TO GET CLOSER TO NATURAL HA

 

HIGH STRENGTH

 

GOOD STRECH

 

ABILITY TO MAINTAIN ITS STRUCTURE

 

UP TO 18 MONTHS DURATION 20

 

BDDE = 1,4-Butanediol diglycidyl ether
 MoD= Degree of Modification
HMW= High Molecular Weight

 

 

 

 

References

1.Teoxane internal data source. Teosyal Redensity 2 deliveries from 2012 to 2020: 1'011'774 boxes

2.Berguiga et al. Orbit, 2017; 36(1):22-26.

3.TEOSYAL ® PURESENSE REDENSITY 2 – instruction for use

4.TEOXANE R&D report RDRE 2023. Data on File. Physical analysis of HA fillers intended for infraborbital uses. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity. . 

5.TEOSYAL RHA® 4 – instruction for use

6.RDRE 2015 - Rheological analysis of Volumizers _ Ultra Deep_RHA4_Lyft_Voluma

7. Michaud et al. J Cosmet Dermatol. 2015; 14(1): 9–21

8. Arcane Research Study conducted in France in March 2018 on 8.646 women from 18 to 75 y/o

9. Teoxane data source TEO-RHA-1902 Injection Guidelines

10. Funt. J Clin Aesthet Dermatol. 2011; 4(12):32-63

11. Bravo et al. J Clin Aesthet Dermatol. 2015; 8(6):30-5

12. Glaser et al. Dermatol Surg 2018; 44:1547-1554

13. Beleznay et al. Dermatol Surg. 2015; 41:1097-1117

14. Teoxane Post Market Surveillance data November 2020. 1445 practitioners worldwide

15. Ramanadham et al. Plast Reconstr Surg. 2015; 136:49S-55S

16.Teoxane Worldwide Survey "Periorbital Treatments in Clinics" by 180 injectors, June 2020

17. Cotofana et al. Facial Plast Surg. 2016; 32:253-260

18. Lemaire. E2e Medical Publishing, Master Collection 2, Paris, 2011

19. Kaufman-Janette et al. J Cosmet Dermatol. 2019; doi: 10.1111/jocd.1310

20. Rzany et al. Dermatol Surg; 2019; 45(10):1304-1314

21. TEOXANE Post-Marketing Surveillance from 2016 to 2020-Q3

22. Data on file 2020. Syneos study report 7010664.SA.259

23. Sharad. J Cutan Aesthet Surg. 2012; 5:229238

24. Sadick et al. Cosmet Dermatol. 2007;6(4):218-22

25. The properties of ingredients derive from data communicated by the raw material manufacturers

26.Efficacy study. Results measured after 28 days of use

 

 

* REDENSITY 2 = TEOSYAL® PureSense REDENSITY 2

# Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL

Find a practitioner

Required fields*

I agree to receive exclusive offers and the latest news from Hyaluronic-acid.com
Choose your country

Close

close
Europe

France

UK

Germany

Italy

Poland

Switzerland

Spain

Russia

International

English

French

Asia Pacific

Australia

Come back to consumer area

You are switching to our professional universe

close